RDY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Dr. Reddy's Laboratories Ltd is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive developments such as FDA acceptance for its biosimilar, the company's recent financial performance shows declining revenue, net income, and EPS. Additionally, technical indicators and trading sentiment do not suggest a compelling entry point at this time. The absence of strong proprietary trading signals further supports a hold recommendation.
The MACD is positive but contracting, indicating a lack of strong momentum. The RSI is neutral at 61.38, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot point of 14.446, with resistance at 14.728 and support at 14.163. Overall, the technical indicators do not signal a strong buy opportunity.
FDA acceptance of the company's 351(k) Biologics License Application for its biosimilar DRL_AB, which targets rheumatoid arthritis and psoriatic arthritis, is a significant positive catalyst. This development could potentially lead to future revenue growth.
Declining financial performance in the latest quarter, with revenue down 1.02% YoY, net income down 18.84% YoY, and EPS down 20.00% YoY. Additionally, gross margin has dropped by 8.61% YoY, indicating operational challenges.
In Q3 2026, the company reported a revenue decline of 1.02% YoY to $979.8 million. Net income dropped 18.84% YoY to $135.8 million, and EPS decreased by 20.00% YoY to $0.16. Gross margin also fell to 53.63%, down 8.61% YoY, reflecting weaker profitability.
No recent analyst rating or price target changes were provided. Wall Street sentiment appears neutral, with no significant hedge fund or insider trading activity reported.
